Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Desmopressin Acetate

FDA-approved product (solution, nasal), marketed as Concentraid, Ddavp, Ddavp (Needs No Refrigeration) and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Desmopressin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central diabetes insipidus
  • Diabetes insipidus
  • Enuresis
  • Head injury
  • Hemorrhage
  • Nasal congestion
  • Nocturia
  • Von Willebrand disease (hereditary or acquired)

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vasopressin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Desmopressin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Desmopressin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Desmopressin Acetate 0.2 mg Tablets, Fasting

    NCT00835211 · start 2003-07

    Registered record
    Registry ID
    NCT00835211
    Conditions
    Healthy
    Interventions
    Desmopressin Acetate 0.2 mg Tablets; DDAVP® 0.2 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-07
    Completion
    2003-08
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDesmopressin Acetate 0.2 mg Tablets; DDAVP® 0.2 mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis

    NCT00245479 · start 2002-04

    Registered record
    Registry ID
    NCT00245479
    Conditions
    Nocturnal Enuresis
    Interventions
    Primary nocturnal enuresis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-04
    Completion
    2006-11
    Enrolment
    802

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocturnal Enuresis
    InterventionPrimary nocturnal enuresis
    PhasePhase 4
    Registry statusCompleted

  • Treatment and Management of Women With Bleeding Disorders

    NCT00111215 · start 2001-01

    Registered record
    Registry ID
    NCT00111215
    Conditions
    Menorrhagia; Blood Coagulation Disorders; Blood Platelet Disorders; Von Willebrand Disease; Hematologic Disease
    Interventions
    Tranexamic Acid; Desmopressin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-01
    Completion
    2006-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenorrhagia; Blood Coagulation Disorders; Blood Platelet Disorders; Von Willebrand Disease +1 more
    InterventionTranexamic Acid; Desmopressin Acetate
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Supine Hypertension in Autonomic Failure

    NCT00223717 · start 2001-01

    Registered record
    Registry ID
    NCT00223717
    Conditions
    Hypertension
    Interventions
    Clonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP); Sildenafil; Nifedipine; Hydralazine; Hydrochlorothiazide; Placebo; Bosentan; Diltiazem; Eplerenone; guanfacine; L-arginine; captopril; carbidopa; losartan; metoprolol tartrate; nebivolol hydrochloride; prazosin hydrochloride; tamsulosin hydrochloride; Head-up tilt.; aliskiren; Local heat stress
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2017-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionClonidine; Nitroglycerin transdermal; Dipyridamole/ Aspirin (Aggrenox); Desmopressin (DDAVP) +20 more
    PhasePhase 1
    Registry statusCompleted

  • Study of Novel Types of Familial Diabetes Insipidus

    NCT00004364 · start 1995-12

    Registered record
    Registry ID
    NCT00004364
    Conditions
    Diabetes Insipidus
    Interventions
    desmopressin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    1995-12
    Completion
    Not recorded
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Insipidus
    Interventiondesmopressin
    PhaseNot recorded
    Registry statusUnknown